QA: SYBLEU Inc in us_pharma/2022

Table of Contents

See also this year's filing and all EDGAR filings for this company.

PDF Report 0001818674_2023_SYBLEU_Inc.pdf

Logs

warning Missing logo subcommand.report {}
info Minor missing amount for aggregate added to remainder industry.us_generic {'aggregate': 'Expenses', 'missing_ratio': 1.4689896289332198e-05, 'aggregate_val': 68073, 'exp_sum': 68074, 'exp_to_value': {'CostOfGoodsAndServicesSold': 0, 'SellingGeneralAndAdministrativeExpense': 15616, 'ResearchAndDevelopmentExpense': 5058, 'remainder_Expenses': 47400}}
info Minor missing amount for aggregate added to remainder industry.us_generic {'aggregate': 'Liabilities', 'missing_ratio': 3.0642981684689845e-06, 'aggregate_val': 326338, 'exp_sum': 326339, 'exp_to_value': {'LiabilitiesCurrent': 164640, 'LiabilitiesNoncurrent': 0, 'remainder_Liabilities': 161699}}

Graph

Absolute values for 0001818674, SYBLEU Inc

  xvar xval
0 AssetsCurrent 66,850
1 IntangibleAssetsNetIncludingGoodwill 0
2 PropertyPlantAndEquipmentNet 0
3 remainder_Assets 9,529
4 LiabilitiesCurrent 164,640
5 LiabilitiesNoncurrent 0
6 remainder_Liabilities 161,698
7 CostOfGoodsAndServicesSold 0
8 SellingGeneralAndAdministrativeExpense 15,616
9 ResearchAndDevelopmentExpense 5,058
10 remainder_Expenses 47,399
11 remainder_Revenues 11,700
12 remainder_NetIncome -188,973
13 remainder_ComprehensiveNetIncome 0
  yvar yval
0 Assets 76,379
1 Liabilities 326,338
2 Expenses 68,073
3 Revenues 11,700
4 StockholdersEquity -249,959
5 NetIncome -245,346
6 ComprehensiveNetIncome -245,346
7 BaseVar 335,732
8 EconomicCapitalRatio -3.35

Edgar->Model Mapping

Feature Distribution

Change over Time